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Abstract: According to Regulation No. 53 of 2015 of the Minister of Health of the 
Republic of Indonesia, a high risk of HBV infection in health workers is a problem that 
requires attention, and vaccination knowledge is critical to reducing these risk factors. 
Furthermore, because some people do not produce a sufficient antibody-forming (anti-
HBs) response to HBsAg, testing for evidence of protective immunity against hepatitis 
B vaccination is required (Hepatitis B Surface Antigen). The purpose of the study was 
to determine the mapping of the characteristics of anti-HBs antibodies response after 
hepatitis B vaccination in health workers in terms of age, gender, ethnicity, smoking 
habits, obesity, vaccination frequency, last time of vaccination. Sixty vaccinated health 
workers were used to creating the research sample. Anti-HBs levels/titers in serum 
were measured using the Enzyme-Linked Immunosorbent Assay (ELISA) method, 
and a questionnaire was used to compile the data for this study. Age, gender, smoking, 
obesity, and vaccination dose were all used to map the outcomes of the anti-HBs 
antibody immune response study. Anti-HBs antibody response in health workers was 
graded as poor in 36 people (60%) and strong in 24 (40%). Regarding ethnic origin, 
lifestyle, obesity, and vaccination dose (frequency), there was no significant link 
between post-vaccination anti-HBs antibody response in health workers. In terms of 
age and gender, there is a strong association between post-vaccination anti-HBs 
antibody responses in health workers. Low antibody titers should be revaccinated to 
enhance anti-HBs titers, and health workers who smoke should quit because it 
reduces the levels of anti-HBs titers produced clinically. 
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INTRODUCTION 
Hepatitis B is a chronic or acute inflammatory liver disease caused by the 
Hepatitis B Virus (HBV). Hepatitis B is difficult to detect because the symptoms do not 
present right away, and some do not appear at all. As a result, many people are 
unaware that they have been infected. From exposure to the virus until the first 
symptoms show, this virus typically takes 1-6 months to develop (Chaurasia R, 2009; 
Levinson W, 2014; Yulia, 2019). 
In 2013, 1.2% of Indonesians had hepatitis, up from 0.6% in 2007. Hepatitis B 
(21.8%), hepatitis A (19.3%), and hepatitis C are the hepatitis kinds that infect the 
Indonesian population (2.5%). Given the scope of the problem and its implications for 
public health, coordinated, targeted, and widespread measures are required to combat 
the hepatitis virus outbreak (Pusdatin Kemenkes RI, 2017; Kemenkes RI, 2019). 
Health workers are a high-risk group for hepatitis B infection, according to the 
Minister of Health of the Republic of Indonesia's Regulation No. 53 of 2015 concerning 
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the control of viral hepatitis. Professionals related to health services are vulnerable to 
direct contact with the patient's blood and body fluids. HBV can be transmitted through 
contact with infected blood or body fluids and damage from contaminated sharp items 
such as needles. Health workers are four times more likely than the general population 
to get Hepatitis B infection due to regular contact with patient's blood and body fluids 
(Kemenkes RI, 2015).  
Unvaccinated people have a 6–30% chance of contracting Hepatitis B after a 
single exposure. According to the WHO, over 66,000 health workers worldwide are 
exposed to blood-borne HBV infections every year. Suppose a health worker is 
infected by mistake. In that case, there is a 1% chance of developing fulminant 
hepatitis, a 4% chance of developing chronic (active) hepatitis, and a 5% chance of 
becoming a virus carrier (Sahana et al., 2017). According to Roggendorf & Viazov 
(2003), health workers are infected with HBV at a high incidence, with 5-10% of 
infected people being chronic HBV carriers. In circumstances of direct blood contact, 
such as surgery, hemodialysis units, or oncology wards, HBV transmission is 
widespread. Vaccination can also prevent HBV spread from patients to health workers.  
The high risk of HBV infection among health care professionals is a problem 
that must be addressed, and vaccination knowledge is critical in reducing these risk 
factors. HBV infection can be prevented with vaccination. Furthermore, because some 
people do not produce a sufficient antibody-forming (anti-HBs) response to HBsAg, 
testing for evidence of protective immunity against hepatitis B vaccination is required 
(Hepatitis B Surface Antigen). According to field observations, few health workers still 
do not perform a response test for the production of anti-HBs after vaccinating for 
hepatitis B to establish post-vaccination antibody titers. Because data from this test 
will be used to determine whether the anti-HBs produced effectively protect against 
hepatitis B infection. After immunization, an anti-HBs titer of >10 mIU/ml is considered 
an immunological marker that confers protection against infection (Zuckerman et al., 
1997). 
A study has shown that 10.5% of all successfully vaccinated people have not 
achieved a minimum level of antibody protection of 10 mIU/ml, 10.5% have antibody 
levels in the 11-100 mIU/ml range, 79% have antibody levels >101 mIU. /ml (Rao, S 
& Sathiavathy., 2008). Another study conducted on 112 health workers showed that 
the level of protective antibodies was 99.9% after one year of vaccination and 
decreased to 80.96% and 46.16% after 5 and 10 years of vaccination (Mahawal et al., 
2013). According to Tripathy et al. (2011), the immune response to vaccination is 
influenced by several factors, including age, gender, obesity, smoking, immunity, and 
genetic factors. In this study, the immune response of antibody formation after 
hepatitis B vaccination was associated with sex, age, ethnicity, smoking habits, body 
mass index leading to obesity, vaccination dose, and time of last vaccination. 
 Based on data from the Banjarbaru and Banjar Health Offices in 2019, which 
had conducted HBsAg tests on health workers in the region. The examination results 
found that one health worker had reactive HBsAg, and only about 24% of health 
workers had been vaccinated against hepatitis B. In addition, of all the health workers 
who had been vaccinated, it turned out that they had never tested for anti-HBs 
antibodies. Therefore, based on this case, the study followed up on anti-HBs 
examination after hepatitis B vaccination in terms of age, sex, smoking, obesity, and 
frequency of vaccination to health workers. The data obtained from this study will be 
aimed at mapping the strong response and weak response to the formation of anti-
HBs antibodies after hepatitis B vaccination in terms of age, gender, smoking habits, 
obesity, vaccine dose, and last time of vaccination. 
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MATERIALS AND METHODS 
An analytic survey with a cross-sectional study design was used in this 
investigation. The sample used in this study was serum from health workers in Banjar 
and Banjarbaru district and students of Poltekkes Kemenkes Banjarmasin. They had 
been vaccinated with hepatitis B, with up to 60 samples collected using consecutive 
sampling techniques within a certain period. This research has been submitted to the 
Ethics Commission with the reference number 011/KEPK-RSDI/VII/2021 at Health 
Research Ethics Committee Idaman District Hospital of Banjarbaru. 
Respondents vaccinated against hepatitis B were given informed consent, 
filled out a questionnaire, and collected three ccs of venous blood to check the anti-
HBs antibody titer using the ELISA (Enzyme-Linked Immunosorbent Assay) method, 
namely ELISA Reader with Zenix brand specifications. The results of the antibody titer 
examination were then mapped according to the characteristics of the respondents in 
terms of several aspects such as age, gender, smoking, obesity, vaccination dose, 
duration of the vaccine. In addition, the mapping of respondents' characteristics from 
the results of laboratory tests on anti-HBs titers was divided into two titer levels: <100 
mIU/mL as a weak antibody response and 100 mIU/mL as a strong antibody response. 
The data that has been collected is then processed using the standard statistical 
software. Data related to respondent characteristics such as age, gender, smoking, 
obesity, vaccination dose, last duration of vaccine, and data on anti-HBs test results 
will be described and displayed in tables and diagrams. Data processing used a Chi-
square test to determine the significance of the relationship between age, gender, 
smoking, obesity, vaccination dose, duration of the last vaccine against anti-HBs titer 
formation. A significant relationship was obtained when the p-value <0.05. 
 
RESULTS AND DISCUSSION 
Anti-HBs Antibody Response Status 
The results of an antibody titer examination utilizing the ELISA method were 
used to determine the anti-HBs antibody response. The antibody titers were divided 
into two groups: a weak response (100 mIU/mL) including 36 people (60%) and a 
strong response (100 mIU/mL) involving 24 people (40%). 
  
Table 1. Anti-HBs Antibody Response Status 
Variable N (%) 
Weak Response (< 100 mIU/mL)  36 60 
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Anti-HBs Antibody Response after Vaccination and Respondents' 
Characteristics 
 The table above shows the results of data analysis using Chi-Square (table 2). 
The group connected to gender, age, and last time of vaccination had a significance 
value of 0.005. In contrast, the group associated with ethnicity, BMI, smoking habit, 
vaccination frequency, and disease history had a P-value > 0.005.  
Although statistically, there was no association between weak and firm 
responses to the development of anti-HBs antibodies and characteristics such as 
ethnicity, BMI, smoking habits, vaccination frequency, and disease history, clinically, 
it had importance. Due to the unequal distribution of the number of participants in each 
group, the statistics are useless. This can be shown in several ways, one of which is 
the respondents' smoking habits, where it was discovered that all respondents who 
smoked (7 people) had an inadequate response to the development of anti-HBs 
antibodies, despite having been vaccinated recently (within the last 1-5 years). 
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Association of Anti-HBs Antibody Response and Gender 
Based on the data in table 2, it can be seen that the antibody response and 
gender have a significant relationship (P-value 0.005). A solid response to the 
formation of anti-HBs antibodies is more common in women (57.9%), while a weak 
response is more common in men (91%). The results of this study are the following 
studies that state an effect of antibody formation responses based on gender. Several 
studies that have been carried out to determine antibody responses in terms of 
different sexes have found that the male sex has a lower antibody formation response 
than the female sex (Struve, J et al., 1992; Cardell, 2009; Zimmermann, P et al., 2019; 
Jabal, KA et al., 2021). 
Only a few research have looked at the immunological response to vaccines 
concerning gender. The immunosuppressive effect of testosterone induces a 
decreased antibody response to vaccinations in males, mediated via gene expression 
involved in lipid metabolism and related with inhibition of the inflammatory response 
(Bouman et al., 2004; Ortona, E et al., 2019). 
Women's innate and adaptive immune responses (humoral and cellular) are 
generally stronger than men's. TCD4+ cells are found in more significant numbers in 
women than in males, and TCD4+ cells are recognized to play a significant role in 
antibody production (Bouman et al., 2004; Klein, SL et al., 2016; Fink, AL et al., 2018). 
 
 
Figure 2. Association of Anti-HBs Antibody Response and Gender  
 
Association of Anti-HBs Antibody Response and Age 
Figure 3 shows that the age range for forming a solid antibody titer is 24 – 45 
years, while the age range for forming a weak antibody titer is 17 – 25 years. This was 
20 years ago (or vaccinated as a baby). Even though this age group had been 
vaccinated as an adult, the percentage of weak and high antibody responses was 
balanced in the old age group (46 – 65 years). The results showed a significant value 
of the relationship between the response to the formation of anti-HBs antibodies and 
age (table 2). However, this research contradicts the study by Dunn-Walters and 
Wagner, who examined the effects of aging on humoral and cellular immune 
responses. The elderly had significantly lower vaccine-specific antibody titers. Lower 
production of cytokines like interferon-gamma (IFN-γ) correlates with reduced humoral 
immune response in the elderly (elderly). In the elderly, changes in cellular immunity 
and reduced antibody titers are particularly noticeable (Dunn-Walters et al., 2003; 
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Figure 3. Association of Anti-HBs Antibody Response and Age 
 
 Association of Anti-HBs Antibody Response and Ethnic 
The ethnicity data has a non-significant value (P-value > 0.005) (table2). The 
data distribution amongst ethnic groups is not evenly distributed; out of 60 research 
respondents, 39 are from the Banjar tribe, while the remainder is from diverse ethnic 
groups in Indonesia. To assess the association between antibody response and 
ethnicity, limitations in the data distribution must be re-examined and tested utilizing a 
bigger sample and an even distribution of data. 
Previous research has found that the host's genetic factors are responsible for 
forming a solid or weak antibody response (Wang & Lin, 2007; Haralambieva et al., 
2014; Choe et al., 2020). Furthermore, Wang & Lin (2007) found that vaccination 
storage conditions based on geographic location did not affect the value of the anti-
HBs titer produced. 
 
 
Figure 4. Association of Anti-HBs Antibody Response and Ethnic 
 
Association of Anti-HBs Antibody Response and BMI 
 In numerous studies, increased BMI is inversely related to the antibody 
response to Hepatitis B vaccination. Increased BMI was initially associated with a 
more robust antibody response after immunization. Higher BMI was associated with a 
more significant antibody decrease 12 months after vaccination, and obese individuals 
also exhibited fewer specific TCD8+ cells and less IFN- production, suggesting that 
BMI influences vaccine response rate. Furthermore, the decreased vaccination 
response in obese people may be related to the vaccine's predominant distribution in 
fat rather than muscle. Enzymatic action can prevent absorption and facilitate 
denaturation of vaccination antigens. Another possibility is that the proliferation and 
function of antibody-secreting plasma cells are compromised (Cardell, 2009; 
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 In this study, it was not found that Body Mass Index (BMI) affected vaccination 
outcomes. In contrast, in other studies, it has been shown that BMI (table 2 and figure 
5), especially >30, is associated with lower response rates. This study cannot prove 
the relationship between BMI and antibody response because the factors that 
influence the formation of antibody titers cannot be measured only from obesity. The 
data found in non-obese respondents as much as 69% were caused by their BMI but 




Figure 5. Association of Anti-HBs Antibody Response and BMI 
 
Association of Anti-HBs Antibody Response and Smoking Habit 
 Some people who smoke have a poorer antibody response to Hepatitis B 
immunization. Smoking is closely linked to a low vaccine response rate for Hepatitis 
B. Smokers' immunoglobulin levels were found to be lower than nonsmokers'. 
Dendritic cell function is known to be harmed by smoking. Nicotine blocks T-cell 
antibody-forming cell responses by interfering with antigen-mediated pathways and 
intracellular calcium responses. Nicotine inhibits dendritic cell antigen absorption and 
the ability of naive T cells to develop into Th1 cells. In smokers, T cell growth is 
hampered (Winter et al., 1994; Cardell, 2009; Yang et al., 2016; et al., 2019; 
Zimmermann, P., 2019). 
 As shown in table 2 and figure 6, the results showed that seven respondents 
who had a smoking habit produced low antibody titers. However, statistical analysis 
did not show a relationship; clinically, the 100% smokers group of respondents had a 
weak antibody response. This is very much in line with previous studies. 
 
Figure 6. Association of Anti-HBs Antibody Response and Smoking Habit 
 
Association of Anti-HBs Antibody Response and Vaccination Frequency 
 Before the second dose of Hepatitis B vaccination, there was a cell-mediated 
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induced by HBsAg and generation of IFN-γ (2nd dose). The amount of HBsAg-induced 
PBMC proliferation varies from person to person. In addition, cytokines produced in 
response to HBsAg stimulation can activate Th1 or Th2 cells (Cardell, 2009; Tripathy 
et al., 2011; Yang et al., 2016; Zimmermann, P., 2019). 
 Figure 7 shows that respondents who have just received the first dose of the 
vaccine have not been able to form high antibody titers, so the second dose of 
vaccination is necessary. Respondents who had received the second and third doses 
of vaccination obtained higher antibody titers and were better able to protect against 
Hepatitis B infection.  
 
Figure 7. Association of Anti-HBs Antibody Response and Vaccination Frequency 
 
Association of Anti-HBs Antibody Response and Last Vaccination Time 
 Anti-HBs antibody levels decline in the years following vaccination, and in some 
cases, the vaccinated will have anti-HBs levels <10 mIU/mL after five years (Zhao Y 
et al., 2019). Research data shows that respondents who have been vaccinated 
against Hepatitis B within a period of 10-20 years experience a decrease in anti-HBs 
titers, while respondents who have been vaccinated for 0-5 years appear to have a 
weak response because it is influenced by the presence of respondents who have just 
taken one times the dose vaccinated and some other influenced by smoking habits. 
Vaccination has been shown to induce active anti-HBs antibodies accompanied 
by HBsAg-specific immunological memory, which provides continuous protection in 
the absence of antibodies. According to Bagheri-Jamebozorgi, M et al. (2014), the 
persistence of immunological memory for five years after primary vaccination is seen 
from a rapid increase in antibody levels after booster vaccination, even in subjects 
who have lost antibodies. The presence of immunological memory in B lymphocyte 
memory induced during the first exposure to an antigen and upon subsequent 
exposure to the same antigen induces the rapid production of specific antibodies. In 
addition, spotELISA assays have shown that the number of memory B lymphocytes 
capable of producing anti-HBs antibodies does not decrease as antibody levels 
decrease. In other words, the loss of antibodies does not necessarily mean the loss of 
immunity to Hepatitis B virus (HBV) antigen due to the presence of immunological 
memory. Therefore, individuals whose anti-HBs levels drop to <10 mIU/mL may not 
be at risk for liver disease because they have HBsAg-specific immunological memory. 
After exposure to HBV, the presence of immunological memory rapidly leads to a solid 
anamnestic response, which prevents acute disease and chronic infection (Banatvala 
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Figure 8. Association of Anti-HBs Antibody Response and Last Vaccination Time 
 
Association of Anti-HBs Antibody Response and Disease History 
Because the pathophysiology of comorbidities is various, people with them 
frequently have complex and unstable situations. Although some studies have not 
established a link between comorbidity and seroprotection, comorbidity may be a 
critical factor that affects the efficiency of the Hepatitis B vaccination, resulting in 
reduced immunity (immunity). However, the precise mechanism between a poor 
response to the Hepatitis B vaccine and individuals with comorbidities is still unknown 
(Yang et al., 2016). In this study, no significant correlation was found between a 
person's comorbid conditions and the response to the formation of anti-HBs antibodies 
after vaccination (table 2 and figure 9). 
 
 
Figure 9. Association of Anti-HBs Antibody Response and Disease History 
 
In this study, there were still limitations in the number of samples that could not 
represent all the characteristics of the respondents, for example, the types of ethnic 
groups that were not evenly distributed among the selected respondents, as well as 
the characteristics of the number of respondents who had been vaccinated with 
various doses (1 - 3 times), so that in the following research it is necessary to pay 
attention to the number of samples proportionally and represent all the characteristics 
observed in the study. 
 
CONCLUSION 
Health workers who have a weak immune response to the formation of anti-
HBs antibodies are 36 people (60%), and robust immune response is 24 people (40%). 
The longer the time from immunization, the vaccine's effectiveness will decrease 
significantly. Low antibody titers should be revaccinated to enhance anti-HBs titers, 
and health workers who smoke should quit because it reduces the levels of anti-HBs 
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